Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes (Q47420220)

16 January 2018

title

Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes (English)

1 reference

16 January 2018

1 reference

1 reference

2

Robert Silbergleit

1 reference

16 January 2018

author name string

Phillip A Scott

series ordinal

1

1 reference

16 January 2018

language of work or name

English

0 references

publication date

1 November 2003

1 reference

16 January 2018

Annals of Emergency Medicine

published in

1 reference

16 January 2018

volume

42

1 reference

16 January 2018

issue

5

1 reference

16 January 2018

page(s)

611-618

1 reference

16 January 2018

Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Hea

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Emergency physicians. Accuracy in the diagnosis of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Diagnosis of stroke by the nonneurologist. A validation study.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Conditions that mimic stroke in the emergency department. Implications for acute stroke trials

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Intravenous tissue plasminogen activator for acute ischemic stroke: A Canadian hospital's experience

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Treating acute stroke patients with intravenous tPA. The OSF stroke network experience

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Minimizing the risk of inappropriately administering thrombolytic therapy (Thrombolysis and Angioplasty in Myocardial Infarction [TAMI] study group).

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

"Inadvertent" thrombolytic administration in patients without myocardial infarction: clinical features and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2803%2900443-8

7 January 2021

10.1016/S0196-0644(03)00443-8

Identifiers

DOI

1 reference

16 January 2018

1 reference

16 January 2018